Literature DB >> 11720444

p73 is over-expressed in vulval cancer principally as the Delta 2 isoform.

J O'Nions1, L A Brooks, A Sullivan, A Bell, B Dunne, M Rozycka, A Reddy, J A Tidy, D Evans, P J Farrell, A Evans, M Gasco, B Gusterson, T Crook.   

Abstract

p73 was studied in squamous cancers and precursor lesions of the vulva. Over-expression of p73 occurred commonly in both human papillomavirus (HPV)-positive and -negative squamous cell cancers (SCC) and high-grade premalignant lesions. Whereas expression in normal vulval epithelium was detected only in the basal and supra-basal layers, expression in neoplastic epithelium increased with grade of neoplasia, being maximal at both protein and RNA levels in SCC. p73 Delta 2 was the principal over-expressed isoform in the majority of cases of vulval SCC and often the sole form expressed in SCC. Over-expression of p73 was associated with expression of HPV-encoded E7 or with hypermethylation or mutation of p16(INK4a) in HPV-negative cases. There was a close correlation between expression of p73 and p14(ARF) in cancers with loss of p53 function. The frequent over-expression of p73 Delta 2 in neoplastic but not normal vulval epithelium, and its co-ordinate deregulation with other E2F-1 responsive genes suggests a role in the oncogenic process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720444      PMCID: PMC2363945          DOI: 10.1054/bjoc.2001.2138

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  New p73 variants with altered C-terminal structures have varied transcriptional activities.

Authors:  Y Ueda; M Hijikata; S Takagi; T Chiba; K Shimotohno
Journal:  Oncogene       Date:  1999-09-02       Impact factor: 9.867

2.  p63 and p73 transactivate differentiation gene promoters in human keratinocytes.

Authors:  V De Laurenzi; A Rossi; A Terrinoni; D Barcaroli; M Levrero; A Costanzo; R A Knight; P Guerrieri; G Melino
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

3.  Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus.

Authors:  L A Brooks; J A Tidy; B Gusterson; L Hiller; J O'Nions; M Gasco; M C Marin; P J Farrell; W G Kaelin; T Crook
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  Analysis of p73 in human borderline and invasive ovarian tumor.

Authors:  S W Ng; G K Yiu; Y Liu; L W Huang; M Palnati; S H Jun; R S Berkowitz; S C Mok
Journal:  Oncogene       Date:  2000-04-06       Impact factor: 9.867

5.  Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53.

Authors:  I Fillippovich; N Sorokina; M Gatei; Y Haupt; K Hobson; E Moallem; K Spring; M Mould; M A McGuckin; M F Lavin; K K Khanna
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

6.  Oncogenes induce and activate endogenous p73 protein.

Authors:  A Zaika; M Irwin; C Sansome; U M Moll
Journal:  J Biol Chem       Date:  2000-12-13       Impact factor: 5.157

7.  Role for the p53 homologue p73 in E2F-1-induced apoptosis.

Authors:  M Irwin; M C Marin; A C Phillips; R S Seelan; D I Smith; W Liu; E R Flores; K Y Tsai; T Jacks; K H Vousden; W G Kaelin
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

8.  A common E2F-1 and p73 pathway mediates cell death induced by TCR activation.

Authors:  N A Lissy; P K Davis; M Irwin; W G Kaelin; S F Dowdy
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

Review 9.  Carcinoma of the vulva: epidemiology and pathogenesis.

Authors:  C P Crum
Journal:  Obstet Gynecol       Date:  1992-03       Impact factor: 7.661

10.  HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes.

Authors:  E W Lam; J D Morris; R Davies; T Crook; R J Watson; K H Vousden
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  9 in total

Review 1.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

2.  Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.

Authors:  Jolynn Zu Lin Ong; Rui Yokomori; Regina Wan Ju Wong; Tze King Tan; Ryuzo Ueda; Takashi Ishida; Shinsuke Iida; Takaomi Sanda
Journal:  Leukemia       Date:  2022-07-30       Impact factor: 12.883

Review 3.  Mechanisms, function and clinical applications of DNp73.

Authors:  Cuixia Di; Lina Yang; Hong Zhang; Xiaofei Ma; Xin Zhang; Chao Sun; Hongyan Li; Shuai Xu; Lizhe An; Xun Li; Zhongtian Bai
Journal:  Cell Cycle       Date:  2013-06-13       Impact factor: 4.534

4.  p53 Family: Role of Protein Isoforms in Human Cancer.

Authors:  Jinxiong Wei; Elena Zaika; Alexander Zaika
Journal:  J Nucleic Acids       Date:  2011-10-09

Review 5.  Advances in real-time PCR: application to clinical laboratory diagnostics.

Authors:  Bernhard Kaltenboeck; Chengming Wang
Journal:  Adv Clin Chem       Date:  2005       Impact factor: 5.394

6.  DNA methylation markers for cancer risk prediction of vulvar intraepithelial neoplasia.

Authors:  Nikki B Thuijs; Johannes Berkhof; Müjde Özer; Sylvia Duin; Annina P van Splunter; Barbara C Snoek; Daniëlle A M Heideman; Marc van Beurden; Renske D M Steenbergen; Maaike C G Bleeker
Journal:  Int J Cancer       Date:  2021-01-10       Impact factor: 7.396

7.  Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Authors:  Stephan Emmrich; Weiwei Wang; Katja John; Wenzhong Li; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2009-08-11       Impact factor: 27.401

8.  DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.

Authors:  Alex I Zaika; Neda Slade; Susan H Erster; Christine Sansome; Troy W Joseph; Michael Pearl; Eva Chalas; Ute M Moll
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

9.  Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Authors:  Zhihui Wang; Mette S Førsund; Claes G Trope; Jahn M Nesland; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2018-07-02       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.